Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for ARGX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 1.160B
December 31, 2025 845.65M
June 30, 2025 542.69M
December 31, 2024 28.85M
June 30, 2024 -145.54M
December 31, 2023 -328.06M
June 30, 2023 -619.12M
December 31, 2022 -851.15M
June 30, 2022 -869.97M
December 31, 2021 -602.62M
June 30, 2021 -472.14M
Date Value
December 31, 2020 -393.48M
June 30, 2020 -248.60M
December 31, 2019 155.39M
June 30, 2019 230.87M
December 31, 2018 -60.44M
June 30, 2018 -57.62M
December 31, 2017 -42.54M
June 30, 2017 -30.13M
December 31, 2016 11.71M
June 30, 2016 15.80M
December 31, 2015 -15.20M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Autolus Therapeutics Plc -224.98M
Akari Therapeutics Plc -10.74M
Forte Biosciences, Inc. -71.98M
Evaxion AS --
DBV Technologies SA -169.35M